Kura Oncology, Inc. Common Stock (KURA) Stock
Key stats
- Market cap
- $710.22M
- Price / Earnings ratio
- -2.3x
- EPS (TTM)
- -$3.37
- Volume
- Loading
- 52-week high
- $13.90
- 52-week low
- $6.75
Source: third-party data provider, as of November 13, 2026
Compare with KURA
Recent news

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
KURA

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
KURA

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
KURA

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
KURA
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 34.71
- MACD 12/26/9
- -0.79
- EMA 9 of MACD
- -0.60
- MACD histogram
- -0.19
- SMA 50
- $10.39
- Price below SMA 50
- EMA 50
- $9.86
- Price below EMA 50
- SMA 200
- $9.78
- Price below SMA 200
- EMA 200
- $9.96
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
KURA

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
KURA

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know
KURA

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?
KURA

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
KURA

KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook
KURA

Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
KURA

Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy?
KURA

Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect?
KURA

Why Is KURA Stock Rallying 8% After-Hours?
Why Is KURA Stock Rallying 8% After-Hours?
KURA
News tone: automated (AI) classification of the article's content, not a price prediction.
About Kura Oncology, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Troy Edward Wilson J.D., Ph.D. | Chairman, CEO & President | 1969 |
| Ms. Kathleen Ford | Chief Operating Officer | 1947 |
| Mr. Brian T. Powl M.B.A., M.S. | Chief Commercial Officer | 1974 |
| Mr. Thomas Doyle | Senior Vice President of Finance & Accounting | 1971 |
| Dr. Francis J. Burrows Ph.D. | Chief Scientific Officer | 1962 |
| Mr. Greg Mann | Senior Vice President of Investor Relations & Corporate Affairs | — |
| Ms. Teresa Brophy Bair Esq., J.D. | Chief Legal Officer & Corporate Secretary | 1971 |
| Dr. Roger Bakale Ph.D. | Senior Vice President of Manufacturing & Supply Chain | — |
| Dr. Mollie Leoni M.D. | Chief Medical Officer | 1978 |
| Mr. Samir Vattompadam M.S. | Senior Vice President of Global Program Leadership | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 34.71
- MACD 12/26/9
- -0.79
- EMA 9 of MACD
- -0.60
- MACD histogram
- -0.19
- SMA 50
- $10.39
- Price below SMA 50
- EMA 50
- $9.86
- Price below EMA 50
- SMA 200
- $9.78
- Price below SMA 200
- EMA 200
- $9.96
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $24.00
- Average
- $27.00
- High
- $30.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -20.0 | +4.9 | ||||||||||
| 2022 | -4.1 | +15.8 | +0.6 | -14.3 | -12.1 | +35.0 | -17.2 | -7.2 | -9.3 | +18.7 | -1.4 | -20.3 |
| 2023 | +14.7 | -14.2 | +2.3 | -23.8 | +27.6 | -21.6 | -1.5 | -4.0 | -9.3 | -1.7 | +21.0 | +44.4 |
| 2024 | +31.1 | +0.3 | -1.2 | -10.1 | +1.6 | -2.8 | -1.8 | +4.3 | -3.3 | -13.0 | -34.6 | -22.2 |
| 2025 | -8.9 | -6.5 | -9.0 | +2.8 | -12.3 | -8.4 | +8.0 | +31.2 | +11.3 | +11.6 | +24.3 | -9.2 |
| 2026 | -21.5 | +5.6 | -6.3 | +5.9 | +16.3 | +21.3 | -16.4 | +37.6 | -16.9 | -3.7 | -21.0 |



